• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 20, 2019

View Archived Issues

Micurx preps China NDA for next-gen oral oxazolidinone

Shanghai-based Micurx Pharmaceuticals Inc. is preparing to file an NDA for its lead antibacterial candidate, contezolid, with China's National Medical Products Administration after results of a pivotal phase III trial there showed the drug providing comparable clinical cure rates to linezolid for complicated skin and soft tissue infections (cSSTI). Reduced hematologic toxicity for the tablet-based antibiotic vs. linezolid was also seen, highlighting one of contezolid's key advantages. Read More

Boundless Bio raises $46.4M in series A, aims to tackle cancer by targeting ecDNA

As is often the case, it was a personal and devastating encounter with disease that brought Paul Mischel, a founder of newly launched Boundless Bio Inc., to the life sciences. When he lost his father to cancer, he dedicated his career to finding a cure. Read More

South Korean biopharma industry downturn due to series of negative events

SEOUL, South Korea – Biotech investors in South Korea are carefully assessing the outlook for the industry after a series of scandals and reverses have rocked a sector touted as a key area for development in the country. Read More

Mutation hotspots don't always signal drivers

In the world of cancer genomics, mutational hotspots and cancer drivers are used somewhat interchangeably. "It was common knowledge... that if you see a site [mutated] in many cancers, that site is a driver," Gad Getz told BioWorld. But Getz, who is director of the Cancer Genome Computational Analysis Group at the Broad Institute of MIT and Harvard, and his team argue that the conventional wisdom is incorrect. Read More

Coalition pushing to quickly DISARM antimicrobial resistance

Although various government incentives have been introduced in the past few years to encourage and support more research and development designed to accelerate the discovery of new antibiotics, they, in themselves, have not been enough. Read More

Other news to note

Caribou Biosciences Inc., of Berkeley, Calif., granted Oxford Nanopore Ltd., of Oxford, U.K., a worldwide, nonexclusive license under foundational CRISPR/Cas9 intellectual property controlled by Caribou for nanopore sequencing. CRISPR/Cas9-mediated enrichment for nanopore sequencing enables targeted sequencing and is designed to reduce cost, data output and turnaround time. Read More

Regulatory front

The Biosimilars Working Group, made up of diverse patient advocacy organizations, is speaking out against a decision by Canada's British Columbia provincial government to no longer cover Remicade (infliximab, Johnson & Johnson) in treating inflammatory bowel disease. Read More

Financings

Biocurepharm Korea, a subsidiary of Biocure Technology Corp., of Vancouver, British Columbia, closed a convertible debt financing. The company grossed CA$445,600 (US$335,000) issuing 4 units at CA$111,400 per unit. Read More

Clinical data for Sept. 19, 2019

Read More

Regulatory actions for Sept. 19, 2019

Read More

Democrats' Rx pricing plan bashed for content, vilified as a political ploy

Although House Speaker Nancy Pelosi (D-Calif.) has yet to release the actual text of her Lower Drug Prices Now Act, the Democrat plan, unveiled in summary form Thursday, is being fast-tracked through the House with a hearing scheduled Wednesday before the Energy and Commerce Committee. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe